A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...
A new study from the University of Minnesota Medical School has demonstrated that fecal microbiota transplantation (FMT) can ...
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...
By Dennis Thompson HealthDay ReporterTHURSDAY, April 9, 2026 (HealthDay News) — Prompt treatment with a fecal transplant can ...
A new study from the University of Minnesota Medical School demonstrated that fecal microbiota transplantation (FMT) can rapidly reverse systemic inflammation and improve survival in patients with ...
Non-antibiotic drugs with the greatest observed risks for C. difficile infection were antidiarrheals, analgesics, and ...
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...
A new study from the University of Minnesota Medical School demonstrated that fecal microbiota transplantation ...
A new study from the University of Minnesota Medical School demonstrated that fecal microbiota transplantation (FMT) can rapidly reverse systemic inflammation and improve survival in patients with ...
A vancomycin pulse and taper regimen was superior to a standard pulse regimen for the prevention of recurrent CDI.
A single dose of RBL shows treatment success and low readmission rates for patients hospitalized with recurrent CDI.
Some people are horrified by what I do, and run screaming from my office,” says Dr Elizabeth Hohmann, a Harvard-educated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results